MNKD

MannKind Corp.'s stock price has experienced significant fluctuations and a general decline over the past six months, decreasing by approximately 36.90% over the last year. Key events impacting the stock price between March 2026 and September 2026 include a 39% drop on February 25, 2026, following United Therapeutics' announcement of Tresmi, a new soft mist inhaler potentially impacting Tyvaso DPI royalties. MannKind participated in investor conferences on March 10-11, 2026, and presented again on September 10 & 15, 2026. The company released its Q1 2026 earnings report on May 6, 2026. On July 23, 2026, MannKind received FDA approval for Furoscix ReadyFlow, a high-concentration autoinjector. Positive Phase 1b INFLO-1 results, demonstrating the safety and tolerability of Nintedanib DPI, were reported on July 29, 2026. Q2 2026 financial results on August 5, 2026, showed a 43% year-over-year revenue growth to $109.4 million, surpassing estimates, despite an adjusted net loss of $2.7 million and a 7% decline in Afrezza sales. On September 9, 2026, MannKind announced a worldwide licensing and collaboration agreement with Rose Pharma Inc. for ROSE-010 Technosphere, an inhaled GLP-1 for weight management, which led to a negative investor reaction due to its early-stage nature and limited near-term revenue visibility. Ongoing insider selling activity and analyst rating changes with price target adjustments have also been noted.